TIBET RHODIOLA PHARMACEUTICAL HOLDING CO. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.6 CNY | +0.49% |
|
+2.81% | -2.50% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 54% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- With a P/E ratio at 8.86 for the current year and 7.39 for next year, earnings multiples are highly attractive compared with competitors.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -2.50% | 1.62B | - | ||
| +26.47% | 661B | C+ | ||
| +26.74% | 566B | B | ||
| -6.33% | 352B | C+ | ||
| +19.35% | 332B | B- | ||
| +4.23% | 283B | C+ | ||
| +13.43% | 231B | B+ | ||
| +4.71% | 200B | B- | ||
| -9.53% | 195B | A+ | ||
| -4.04% | 145B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600211 Stock
- Ratings Tibet Rhodiola Pharmaceutical Holding Co.
